



BIOMEDICAL SCIENCES

Biological Activities of Species of the Genus *Clusia* L (Clusiaceae): A General Approach

MÁRCIA PIETROLUONGO, MARIA CAROLINA ANHOLETI, ANDRÉ L. FULY,
ALESSANDRA L. VALVERDE & SELMA R. DE PAIVA

Abstract: The genus *Clusia* L. is highly diverse in Central and South America, comprising about 300 species, including trees and shrubs, hemiepiphytes, epiphytes, and lianas. This genus deserves attention due to its wide range of biological activities. *Clusia* belongs to the Clusiaceae family, chemically characterized by the presence of xanthonenes, benzophenones, flavonoids, coumarins, terpenoids, and other substances with bioactive activity already described. This review aims to highlight the biological activity associated to extracts and isolated substances from species of the *Clusia* genus, including anti-HIV, antimicrobial, antioxidant, antinociceptive, antitumor, leishmanicidal, modulator of inflammatory processes, neutralization of toxic effects caused by snake bites, and others. This review gathered information on biological activities associated with different types of extracts and isolated substances of the genus *Clusia*, traditional use, chemical profile, and biological properties of plants of the genus, published in the last 23 years (1998 to 2021) and that can provide support for future research. The paper aims to provide an overview of existing knowledge about the biological properties of the genus *Clusia* plant species.

Key words: Biological activity, *Clusia* sp., Clusiaceae, extraction, isolation, natural products.

INTRODUCTION

Among plants with therapeutic contribution, a considerable number are known through popular wisdom, but knowledge about the chemical and bioactive constitution is limited. The Clusiaceae Lindl. family (= Guttiferae Juss.) fall into this context and comprises approximately 14 genera and 800 species of wide geographical distribution, with significant occurrence in the tropics (Anholeti et al. 2017). The family is chemically characterized by the presence of xanthonenes, benzophenones, flavonoids, coumarins, terpenoids, steroids, among other substances of importance in the plant's biology and in studies of potential biological activity

(Sacramento et al. 2007, Wu et al. 2014, Alves et al. 1999, 2000).

Arawakia L. Marinho, *Chrysochlamys* Poepp., *Clusia* L., *Garcinia* L., *Lorostemon* Ducke, *Mammea* L., *Moronobea* Aubl., *Platonia* Mart., *Symphonia* L.f., *Tovomita* Aubl., *Tovomitopsis* Planch. & Triana, *Dystovomita* (Engl.) D'Arcycom are the genera that occur in regions of Brazil with phylogenetic domains in the Amazon, Caatinga, Cerrado, and Atlantic Forest (Gasparotto Júnior et al. 2005).

The genus *Clusia* is highly diversified in Central and South America comprising about 300-400 species including trees and shrubs, hemiepiphytes, epiphytes, and lianas (Oliveira et al. 1999). *Clusia* species have entire, coriaceous and succulent leaves and the fruits are capsules,

with five or five to ten persistent stigmas, each corresponding to a store in which the seeds are located. The seeds are oval, with a smooth surface of yellowish or vinaceous color, always coated by an orange membranous aryl. Despite the uniformity observed in the leaves, in other aspects, there is a great diversity among the species of this genus, as well as huge metabolic plasticity (Winter et al. 2008).

These plants are resistant to water scarcity and highly adaptable to adverse conditions. Succulent leaves, latex production, and the ability to change photosynthetic metabolism provide the genus the advantages needed to remain all over the planet (Oliveira et al. 1999, Luttge 2006, Winter et al. 2008). *Clusia* is the only genus of tree eudicotyledons capable of performing crassulacean acid metabolism (CAM). Most species of this genus can change their C3 metabolism (the photosynthetic mechanism that involves an intermediate formed by three carbons) to CAM under water restriction conditions, while others are constitutive CAM species (Winter et al. 2008, 2009).

The vast majority of *Clusia* species are dioecious. The production of resins in the stamens and/or pistils of their flowers acts as a reward for female bees who, when seeking for material the construction of their nests, perform pollination (Porto et al. 2000). Research involving the chemical composition of *Clusia* floral resins revealed that they are mainly composed of polyisoprenylated benzophenones and fatty acids. Some species can also produce staminal oils to reduce the viscosity of floral resins so that their composition can vary considerably among the species that make up the genus. (Oliveira et al. 1999, Porto et al. 2000, Luttge 2006, Winter et al. 2008, 2009, Anholeti et al. 2015b).

The literature data revealed that *Clusia* species have several biological activities, including anti-HIV, antimicrobial, antioxidant,

antinociceptive, antitumor, leishmanicidal, modulating activity of inflammatory processes, and neutralization of toxic effects caused by venomous snake bites. Furthermore, several species of the genus have been used in traditional medicine. Among the species we can highlight: *Clusia amazonica*, *C. coclensis*, *C. grandifolia*, *C. insignis*, *C. lineata*, *C. opaca*, *C. palmicida*, *C. planchoniana* and *C. purpurea*. A summary of their traditional usage is presented in Table I

Natural products' chemical diversity and biological properties have been the target of studies for many years. Advances in bioassay techniques, phytochemical studies, and high-performance analytical methods increased the possibilities of discovering new natural compounds with therapeutic potential, boosting studies in this sense (Valli et al. 2018). Despite the growing interest in the classes of substances present in the genus *Clusia*, there is a lack of review articles gathering aspects related to the biological activity of these compounds. Therefore, this review aims to highlight the biological activity of extracts and substances isolated from species of the genus.

MATERIALS AND METHODS

This is a study with data collection carried out from secondary data through a bibliographic survey, search and database analysis. The search used the keywords defined for the object of study and the period ranged from January 1992 to September 2021. This review used the keywords in different scientific literature databases: National Library of Medicine / NLM (PubMed), Science Direct, Web of Science, Scopus, and Scientific Electronic Library Online (SciELO). The keywords were: Biological activity; Extraction; Isolation; Natural products; *Clusia* L., Clusiaceae. The following pairs were used to

Table I. Some species of *Clusia* used in folk medicine.

<i>Clusia</i> species	Local name	Country	Plant Organ	Traditional use	Ref.
<i>C. flava</i>	-	México	Leaves	Carminative, headaches, wounds and to treat syphilis	Barrios et al. 1991
<i>C. salvinii</i>	Orelha de coyote	México	-	Treat gonorrhoea and kidney pain	Yasunaka et al. 2005
<i>C. coclensis</i>	Azahar de monte; copey, and copeicillo	Costa Rica	Leaves	Treat hypertension	García-González et al. 1998
<i>C. insignis</i>	-	Colombia	Floral resins	Relief from toothache	Langenhein 2003
	Apuí; cebola-brava, and guapoí	Brazil	Resin	Treat constipation and healing of fissures in the breasts	
	Mê miomio kangô	Brazil	-	Treat infant oral candidiasis	
<i>C. lineata</i>	Came	Peru	Barks and stems	Treat rheumatism	Fenner et al. 2006
<i>C. opaca</i>	-	Colombia	Resiniferous barks	Mixed with the oil from the palm tree <i>Oenocarpus bataua</i> to treat twists and sore joints	Sanz-Biset et al. 2009, Fenner et al. 2006
		Brazil	Resin	Applied on wounds to accelerate healing	
<i>C. palmicida</i>	Came	Peru	Barks	Treat rheumatism, inguinal hernia, and broken bones	Fenner et al. 2006
<i>C. planchoniana</i>	-	Colombia	Resin	Treat toothaches	Sanz-Biset et al. 2009
<i>C. purpurea</i>	Cebola-brava	Brazil	Inner bark	Antiseptic and wound scarrant	Fenner et al. 2006
<i>Clusia</i> sp.	Came	Peru	Barks	Macerated in rum with <i>Calliandra angustifolia</i> , <i>Monteverdia macrocarpa</i> (= <i>Maytenus macrocarpa</i>), <i>Tovomita foldatsii</i> and <i>Tovomita stylosa</i> used as a tonic	Sanz-Biset et al. 2009
<i>Clusia</i> sp.	Came	Peru	Barks and stems	Treat rheumatism	Sanz-Biset et al. 2009

refine the search: *Clusia* L. AND Biological activity. As an exclusion criterion, all articles that did not address the study's subject and were not written in Portuguese, English, or Spanish were removed from the search. Subsequently, the eligibility of the studies identified in the search was assessed by reading the titles and abstracts. All those that addressed the biological activity of the genus *Clusia* were read in full. The analysis of scientific publications focused on searching for experimental or observational articles that

describe studies with the recognized biological activity of the genus *Clusia*.

RESULTS

After reading the 243 abstracts, 97 articles were selected, which were read in full and dealt with *Clusia* L. and biological activity. Of these, 73 articles were selected and discussed. The articles were analyzed, presented, and their descriptive data discussed. The analysis of

scientific publications was carried out with a focus on seeking articles with an experimental or observational design that described studies with the recognized biological activity of the genus *Clusia*.

The Table II describes the biological activities of extracts and substances (Figure 1) isolated from species of the genus *Clusia* (Clusiaceae).

Anti-HIV activity

Acquired Immunodeficiency Syndrome (AIDS), an infectious disease caused by the Human Immunodeficiency Virus (HIV) that drastically reduces the number of CD4 T cells, is still a worldwide concern. Although the replication cycle of HIV is well known and antiretroviral drugs are available, efforts to develop new pharmaceutical alternatives, which started a long time ago, continue to be conducted, and plant sources have aroused the interest of researchers (Salehi et al. 2018, Reutrakul et al. 2007, Márquez et al. 2005, Rukachaisirikul et al. 2003, Spino et al. 1998). The species of *Clusia* have been described as a promising matrix of bioactive substances for this purpose.

In 1992, studies conducted by Gustafson and collaborators, tracking HIV activity in extracts of plant species, found a series of compounds with potential activity, and phytochemical studies led to the isolation of a series of new polyisoprenylated benzophenone derivatives called guttiferones with the ability to inhibit the cytopathic effects of HIV infection *in vitro*. The study describes that the organic extract (CHCl₂:MeOH, 1:1) of leaves of *Clusia rosea*, collected in the Dominican Republic, is mainly composed of guttiferone E and xantochymol. The active compounds inhibited the cytopathic effects of HIV infection *in vitro* in lymphoblastoid CEM-SS cells, with an EC₅₀ value of 1-10 µg/mL. In comparison, cytotoxicity occurred at higher concentrations of 50 µg/mL. However, it did not

inhibit the activity of the reverse transcriptase enzyme (RT) involved in the AIDS infection mechanism.

Huerta-Reyes et al. 2004 tested organic extracts of leaves in dichloromethane and methanol (CHCl₂:MeOH, 1:1, 50 mg/mL) of 10 species of the *Clusia* genus, abundant in Mexico, to verify the ability to inhibit the reverse transcriptase enzyme (RT) involved in HIV-1 infection, through immuno-radioactive and colorimetric assay. Leaves extracts of *Clusia guatemalensis* and *C. massoniana* showed 70.8% and 72.9% of inhibition, respectively, which was considered a high percentage of inhibition (≥ 70%). The species *C. quadrangula* (leaves extract) presented inhibition of 65.6%, considered as moderately active. However, when submitted to the inhibition test of replication of HIV-1 IIIb / LAV, the *C. quadrangula* extracts exhibited less than 52% inhibition.

Piccinelli et al. 2005 described potential HIV activity in *C. torresii*, an endemic species in Costa Rica. The study was conducted with polyisoprenylated benzophenone isolated from the hexanic extract of the fruits, and the results corroborate Huerta-Reyes' studies presenting promising anti-HIV results. Nemorosone and 7-epi-Clusianone showed moderately potent anti-HIV activity with EC₅₀ 0.80 and 2.0 µM, respectively. A study of the mechanism of action showed that the benzophenone derivatives, Clusianone and 7-epi-Clusianone, inhibited gp120-s CD4 interaction suggesting interference at the onset of HIV infection and potential preventive activity with neutralization of infectivity by more than 99% when incubated with the virus at 0.05 and 10 µM, respectively, for 60 minutes at 37 °C, suggesting Clusianone and 7-epi-Clusianone as promising candidates for other studies of HIV infection (Piccinelli et al. 2005, Huerta-Reyes et al. 2004).

Table II. Biological activities described for extracts and substances isolated from species of the genus *Clusia* (Clusiaceae).

Species	Extracts/ substances	Plant organ (solvent)	Biological activities	Dose	IC ₅₀	MIC / MBC	Ref.
<i>C. coclensis</i>	Extract	Leaves (H ₂ O)	Hypotensive effect on normotensive and hypertensive rats	40 mg/Kg	ND	ND	García-González et al. 1998, García-González et al. 1996
<i>C. columnaris</i>	Extract	Stems (CH ₃ OH:CH ₂ Cl ₂)	Antimicrobial activity against <i>Enterococcus faecalis</i> (EF) and <i>Pseudomonas aeruginosa</i> (PA)	ND	ND	EF: MIC = 180 µg/mL; MBC = 270 µg/mL PA: MIC = 140 µg/mL; MBC > 200 µg/mL	Suffredini et al. 2006, Bittar et al. 2000
	13, 118-Binaringerin (1)	Leaves (CH ₃ OH)	Antinociceptive effect in mice	ND	IC ₅₀ (writhing test) = 22 µmol/kg IC ₅₀ (formalin test) = 28 µmol/kg	ND	
<i>C. grandiflora</i>	Resins	Staminate flowers	Antimicrobial activity against <i>Staphylococcus aureus</i> , <i>Bacillus subtilis</i> , and <i>Candida albicans</i> in bioautography assay	ND	ND	ND	Porto et al. 2000, Lokvam et al. 2000, Diaz-Carballo et al. 2012
	Resins	Pistillate flowers	Antimicrobial activity against <i>S. aureus</i> and <i>B. subtilis</i> , in bioautography assay	ND	ND	ND	
	Nemorosone II (2)	Trunk latex (C ₂ H ₅) ₂ O	Antimicrobial activity against <i>Paenibacillus larvae</i> and <i>P. alvei</i> in bioautography assay	ND	ND	ND	
	Chamone I (3)	Pistillate flower (C ₂ H ₅) ₂ O					
7- <i>epi</i> -nemorosone (4)	Floral resins (C ₂ H ₅) ₂ O	Anticancer activity in prostate carcinoma	ND	IC ₅₀ (LNCaP WT) = 4.12±0.19 µM IC ₅₀ (LNCaP ETO MDR1+) = 4.81±0.68 µM IC ₅₀ (PC-3 WT) = 5.01±0.07 µM IC ₅₀ (PC-3 ETO MDR1+) = 5.1±0.1 µM IC ₅₀ (DU-145) = 7.3±0.07 µM IC ₅₀ (DU-145 MDR1+) = 6.8±0.45 µM	ND		
<i>C. guatemalensis</i>	Extract	Leaves (CH ₃ OH:CH ₂ Cl ₂)	Inhibition of HIV-1 virus reverse transcriptase	50 µg/mL	IC ₅₀ (HIV-1 RT) = 42 µg/ml IC ₅₀ (HIV-1 IIIb/LAV) = 124.1 µg/ml	ND	Huerta-Reyes et al. 2004
<i>C. massoniana</i>				50 µg/mL	ND		
<i>C. quadrangula</i>				50 µg/mL	ND		
<i>C. hilariana</i>	Extract	Staminate flowers (CH ₃ OH)	Antifeedant effect on <i>Rhodnius prolixus</i> larvae, and promotion of ecdise delay.	100 µg/mL	ND	ND	Kelecom et al. 2002
	Oleanolic acid (5)		Toxicity on <i>R. prolixus</i> larvae, and promotion of ecdise delay.	1, 10 e 100 µg/mL			
	Nemorosone (6)		Promotion of ecdise delay on <i>R. prolixus</i> larvae	10 µg/mL			

Table II. Continuation.

Species	Extracts/ substances	Plant organ (solvent)	Biological activities	Dose	IC ₅₀	MIC / MBC	Ref.
<i>C. insignis</i>	Resins	Staminate flowers	Antimicrobial activity against <i>S. aureus</i> and <i>B. subtilis</i> in bioautography assay	ND	ND	ND	Porto et al. 2000
<i>C. lanceolata</i>	Resins	Staminate flowers	Antimicrobial activity against <i>S.</i> <i>aureus</i> , <i>B. subtilis</i> and <i>C. albicans</i> in bioautography assay	ND	ND	ND	Porto et al. 2000
	Extract	Non-galled and galled leaves (CH ₃ OH)	Antioxidant activity in β-carotene/ linoleic acid assay	57 µg/mL	ND	ND	Ferreira et al. 2014
<i>C. nemorosa</i>	Resins	Hermaphrodite flowers	Antimicrobial activity against <i>S. aureus</i> and <i>B. subtilis</i> in bioautography assay	ND	ND	ND	Porto et al. 2000
	Extract	Leaves (C ₆ H ₁₄)	Anti-inflammatory and antinociceptive effects on male Swiss mice	62 mg/kg	IC ₅₀ (writhing test) = 62mg/kg	ND	Ferro et al. 2013
			Inhibition of protein exudation, leukocyte influx and TNFα levels on pleurisy induced by carrageenan on male Swiss mice	100 and 200 mg/kg	ND	ND	Farias et al. 2012
	Betulinic acid (7)	Roots (H ₂ O)	Decrease of body weights, abdominal fat accumulation, blood glucose, plasma triglycerides, and total cholesterol on male Swiss mice	50 mg/L	ND	ND	Melo et al. 2009
<i>C. palmana</i>	Extract	Leaves and flower buds (CH ₃ CH ₂ OH:H ₂ O); Leaves and fruits (CH ₃ CO ₂ C ₂ H ₅ fraction)	Neutralization of the hemorrhagic effect induced by <i>Bothrops asper</i> venom in rats	1:50 (poison / extract ratio)	ND	ND	Castro et al. 1999
<i>C. parvicola</i>	Clusiparalicoline A (8)	Roots (CH ₃ CH ₂ OH)	Scission-promoting activity on DNA strands; cytotoxicity in KB cells; growth promotion of neurites in fetal cortical neurons of rats.	neurite outgrowth promoting activity at 1.0 M	ND	ND	Seo et al. 1999, Takaoka et al. 2002
	Clusiparalicoline B (9)		Scission-promoting activity on DNA strands; cytotoxicity in the KB cells			ND	
	Clusiparalicoline C (10)		cytotoxicity in the KB cells			ND	
	Extract	Unripe fruits (CH ₃ CH ₂ OH)	Antioxidant activity	ND	EC ₅₀ (DPPH) = 12.7±0.1; EC ₅₀ (ABTS) = 7.4±0.4;	ND	Oliveira et al. 2012
<i>C. renggerioides</i>	Resins	Staminate flowers	Antimicrobial activity against <i>S. aureus</i> and <i>B. subtilis</i> in bioautography assay	ND	ND	ND	Porto et al. 2000
<i>C. rosea</i>	Guttiferone E (11) and xanthochymol (12)	Leaves (CH ₂ Cl ₂ :CH ₃ OH)	Inhibition of the cytopathic effects of HIV virus in human lymphoblastoid cells	ND	1-10 µg/mL	ND	Gustafson et al. 1992

Table II. Continuation.

Species	Extracts/ substances	Plant organ (solvent)	Biological activities	Dose	IC ₅₀	MIC / MBC	Ref.
<i>C. rosea</i>	Nemorosone (6)	Floral resin (CH ₃ CH ₂ OH)	Cytotoxicity against human cancer cell lines	ND	IC ₅₀ (HELA): 3.3±0.17µM; 1.6±0.08µg/mL IC ₅₀ (HeP-2): 3.1±0.17µM; 1.5±0.08µg/mL IC ₅₀ (PC-3): 7.2±1.3µM; 3.6±0.65µg/mL IC ₅₀ (U251): 3.9±1.4µM; 1.9±0.70µg/mL IC ₅₀ (neuroblastoma cells): 3.10±0.15 - 6.3±0.21µM IC ₅₀ (MCF-7): 0.03 - 0.1µM	ND	Cuesta-Rubio et al. 2002, Díaz-Carballo et al. 2008, Popolo et al. 2011
	7- <i>epi</i> -nemorosone (4)	Resins of pistillate flowers	Antiestrogenic activity	10, 20 and 40 µg/well	ND	ND	Camargo et al. 2013
<i>C. spiritu- sanctensis</i>	Nemorosone (6)	Resins of staminate flowers	Antimicrobial activity against <i>S. aureus</i> and <i>B. subtilis</i> in bioautography assay	ND	ND	ND	Porto et al. 2000
<i>C. torresii</i>	Extracts	Leaves and flowers (CH ₃ CH ₂ OH:H ₂ O) Leaves and fruits (CH ₃ CO ₂ C ₂ H ₅ fraction)	Neutralization of the hemorrhagic effect induced by <i>B. asper</i> venom in rats	1:50 (poison / extract ratio)	ND	ND	Castro et al. 1999
	Clusianone (13)	Fruits (C ₆ H ₁₄)	Inhibition of HIV-1 virus infection in lymphoblastoid T cells (C8166)	ND	IC ₅₀ = 0.020±0.003 µM	ND	Piccinelli et al. 2005
	7- <i>epi</i> -clusianone (14)			ND	IC ₅₀ = 2.0±0.07 µM	ND	
<i>C. weddelliana</i>	Resins	Staminate flowers	Antimicrobial activity against <i>S. aureus</i> and <i>B. subtilis</i> in bioautography assay	ND	ND	ND	Porto et al. 2000
<i>C. fluminensis</i>	Extract	Stems; Leaves; Fruits (H ₂ O)	Antiophidic				Da Silva et al. 2019
	Zeaxanthin (15)	Fruits (not described)	Antioxidant and macular degeneration protector.				Mazza et al. 2019
	Extract	Staminate flowers (C ₆ H ₁₄) Fruits (C ₆ H ₁₄)	Significant reduction of the survival of the insect <i>Oncopeltus fasciatus</i>	1.0 mg/ mL (1.0µg/ insect)	ND	ND	Duprat et al. 2017
	Clusianone (13)	Floral extract (C ₆ H ₁₄)	Reduction on the survival of the insect <i>Dysdercus peruvianus</i>	0.7 mg/ mL (0.7µg/ insect)			
	Lanosterol (16)	Fruit extract (C ₆ H ₁₄)	Significant reduction on both survival and development of the insects <i>O. fasciatus</i> and <i>D. peruvianus</i>				

Table II. Continuation.

Species	Extracts / substances	Plant organ (solvent)	Biological activities	Dose	IC ₅₀	MIC / MBC	Ref.
<i>C. fluminensis</i>	Extract	Leaves (C ₆ H ₁₄ ; CH ₃ OH)	Inhibitory effect of on proteolysis caused by <i>B. jararaca</i> venom	venom / extract ratio: 1:5; 1:10; 1:20; and 1:50	IC _{50(hexane)} : 567µg/mL IC _{50(methanol)} : 447µg/mL	ND	Oliveira et al. 2014
		Stems (CH ₃ OH) ((CH ₃) ₂ CO)			IC _{50(methanol)} : 245µg/mL IC _{50(acetone)} : 180µg/mL		
		Fruits (C ₆ H ₁₄) ((CH ₃) ₂ CO)			IC _{50(n-hexane)} : 736µg/mL IC _{50(acetone)} : 90µg/mL		
	Extract	Staminate flowers (C ₆ H ₁₄)	Significant delay on the development of <i>Aedes aegypti</i>	50 mg/L	ND	ND	Anholeti et al. 2015a
	Clusianone (13)	Staminate flowers (C ₆ H ₁₄)	Significant inhibition of survival and complete blockage of development <i>Ae. aegypti</i>				
<i>C. criuva</i>	Extracts	Leaves (C ₆ H ₁₄ ; CH ₃ OH)	Antioxidant activity in DPPH assay	ND	EC _{50(n-hexane)} : 34.66 ± 19.42 g extract/g DPPH EC _{50(methanol)} : 12.54 ± 1.43 g extract/g DPPH	ND	Da Silva et al. 2017
		Pericarp (C ₆ H ₁₄ ; CH ₃ OH)			EC _{50(n-hexane)} : 10.94 ± 0.36 g extract/g DPPH EC _{50(methanol)} : 5.01 ± 0.16g extract/g DPPH		
		Seeds (C ₆ H ₁₄ ; CH ₃ OH)			EC _{50(n-hexane)} : 8.32 ± 0.30g extract/g DPPH EC _{50(methanol)} : 4.06 ± 1.12g extract/g DPPH		
<i>C. burlemarxii</i>	Extract	Leaves (CH ₃ CH ₂ OH)	Antimicrobial activity against <i>B. subtilis</i> and <i>S. aureus</i>	ND	ND	MIC (<i>B. subtilis</i>): 31.25µg/mL MIC (<i>S. aureus</i>): 62.50µg/mL	Ribeiro et al. 2011
		Trunk (CH ₃ OH)	Antimicrobial activity against <i>B. subtilis</i> , <i>Streptococcus mutans</i> and <i>Micrococcus luteus</i>			MIC (<i>B. subtilis</i>): 62.50µg/mL MIC (<i>S. mutans</i>): 62.50µg/mL MIC (<i>M. luteus</i>): 31.25µg/mL	

Table II. Continuation.

Species	Extracts/ substances	Plant organ (solvent)	Biological activities	Dose	IC ₅₀	MIC / MBC	Ref.
	2,2-dimethyl-3,5-dihydroxy-7-(4-hydroxyphenyl) chromane (17)	Trunk (CH ₃ OH)	Antimicrobial activity against <i>B. subtilis</i> , <i>S. aureus</i> , <i>S. mutans</i> and <i>M. luteus</i>	ND	ND	MIC (<i>B. subtilis</i>): 100µg/mL MIC (<i>S. aureus</i>): 50µg/mL MIC (<i>S. mutans</i>): 100µg/mL MIC (<i>M. luteus</i>): 25µg/mL	
	Lyoniresinol (18)	Leaves (CH ₃ CH ₂ OH)	Antimicrobial activity against <i>S. aureus</i>	ND	ND	MIC (<i>S. aureus</i>): 25µg/mL	
	Rhamnopyranosyl kaempferol (19)		Antimicrobial activity against <i>B. subtilis</i> and <i>S. aureus</i>			MIC (<i>B. subtilis</i>): 50µg/mL MIC (<i>S. aureus</i>): 100µg/mL	
<i>C. gundlachii</i>	Gundlachiione A (20)	Fruits (CH ₃ OH)	Leishmanicidal activity against <i>P. falciparum</i>	ND	IC ₅₀ (promastigote): 11.30µg/mL IC ₅₀ (amastigote): 0.84µg/mL	ND	Zhang et al. 2018
	Gundlachiione B (21)				IC ₅₀ (promastigote): 30.12µg/mL IC ₅₀ (amastigote): 5.92µg/mL		
	Gundlachiione C (22)				IC ₅₀ (promastigote): 9.63µg/mL IC ₅₀ (amastigote): 2.32µg/mL		
<i>C. latipes</i>	Extract	Leaves (C ₆ H ₁₄ ; CH ₃ CO ₂ C ₂ H ₅ ; CH ₃ OH)	Cytotoxic activity against human cancer cell lines (PC-3, RKO, D-384 and MCF-7)	50µg/ml	ND	ND	Bailón-Moscoso et al. 2016
<i>Clusia minor</i>	Extract	Leaves (CH ₂ OH)	Antinociceptive effect on mice	150 and 300 mg/kg	ND	ND	Mangas et al. 2019
<i>Clusia flava</i>	Extract	Leaves (CH ₃ OH)	Leishmanicidal activity against <i>P. falciparum</i>	ND	IC ₅₀ (promastigote): 32µg/mL	ND	Peraza-Sánchez et al. 2007
<i>C. pernanbucensis</i>	Extract	Stem bark (CH ₃ CO ₂ C ₂ H ₅)	Leishmanicidal activity against <i>P. falciparum</i>	ND	IC ₅₀ (amastigote): 65µg/mL	ND	Silva et al. 2013
	Clusiaxanthone (23)				IC ₅₀ (amastigote): 66.9µM		
<i>C. amazonica</i>	Extract	Leaves and stems (H ₂ O)	Leishmanicide				Odonne et al. 2009

Legend: IC₅₀ - Half maximal inhibitory concentration; MIC - Minimum inhibitory concentration; MBC - Minimum bactericidal concentration; ND - Not determined; (H₂O) water; (CH₃CO₂C₂H₅) ethyl acetate; (CH₃OH) methanol; (CH₃)₂CO acetone; (CH₃CH₂OH) ethanol; (CH₂Cl₂) dichloromethane; (C₆H₆) benzene; (C₆H₁₄) *n*-hexane; (C₂H₅)₂O diethyl ether.

Studies carried out by Meneses et al., 2015, with extracts and substances isolated from *C. fluminensis*, showed anti-HIV-1 RT activity. Among the crude extracts, methanolic extracts from leaves and stems showed activity, demonstrating inhibition of about 42 and 20%, respectively, of the HIV-1-RT. In this study, the efavirenz, a reverse transcriptase inhibitor drug used to combat HIV-1 infection, was used as a control, which showed inhibition of about 92%. Two isolated substances were also tested (clusianone and lanosterol) and the triterpenoid lanosterol showed a moderate inhibitory effect ($77.31\% \pm 10.74$). The weak inhibition on HIV-1-RT of the benzophenone clusianone ($37.6\% \pm 1.73$) complements the study of Piccinelli et al. 2005, indicating that the inhibition of the reverse transcriptase enzyme does not represent the main mechanism of action of this substance.

Antimicrobial activity


The indiscriminate use of antimicrobials added to the transmission of genetic resistance among bacterial strains has led to the emergence of resistant bacteria in the available therapeutic arsenal. Therefore, searching for new alternatives is necessary, and natural sources have been studied (Jayasuriya et al. 1991, Nguemaving et al. 2006, Nkengfack et al. 2002, Pecchio et al. 2006, Yimdjo et al. 2004). The *Clusia* genus, the target of this review, has shown antimicrobial activity, especially against gram-positive bacteria.

Suffredini et al. 2006 analyzed organic extracts in dichloromethane and methanol (1:1) produced from *Clusia columnaris* using broth microdilution assay to trace antimicrobial activity against *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Enterococcus faecalis*, and the results were significant (MIC or MBC $\leq 200 \mu\text{g} / \text{mL}$). The extracts were submitted to the determination of the minimal inhibitory concentration (MIC)

and minimal bactericidal concentration (MBC) using gentamicin and tetracycline as standard drugs (García-González & Matamoros 1996). *Pseudomonas aeruginosa* and *E. faecalis* are bacteria related to human infectious diseases, and the results suggest the continuity of studies with the species of *Clusia* and reinforce plants as a source of a new class of antimicrobials.

Studies were conducted to verify the antimicrobial activity of metabolites isolated from resin and latex of *Clusia grandiflora*. The polyisoprenylated benzophenones chamone I and II were isolated from the latex of the trunk of *C. grandiflora*, while nemorosone II from the reward resin of the pollinator of pistillate flowers of the same plant. The bioassays were carried out with *Paenibacillus larvae* and *Paenibacillus alvei*, pathogens that cause diseases in beekeeping and prevent the formation of hives. The substances tested demonstrated potent antibacterial activity against the aforementioned pathogens. The work also described that the abundance of bioactive benzophenones in the resin compared to latex indicates that these compounds benefit bees (Lokvam et al. 2000).

Porto et al. 2000 researched the bioactivity of floral resins of seven species of *Clusia* cultivated at the Agronomic Institute of Campinas, Campinas, São Paulo, Brazil: *C. grandiflora*, *C. insignis*, *C. lanceolata*, *C. nemorosa*, *C. spiritu-sanctensis*, *C. renggerioides*, and *C. weddelliana*. The study was conducted with pistillate and staminate species and considered the influence of methylation of polyisoprenylated benzophenones on antimicrobial potential. Antimicrobial activity was tested using the bioautography test with *Aspergillus niger*, *Bacillus subtilis*, *Candida albicans*, *E. Escherichia coli*, *Rhodococcus equi*, and *S. Staphylococcus aureus*. Chloramphenicol (antibacterial) and nystatin (antifungal) were used for comparison. Bioautography, a trial capable of providing quantitative and



qualitative information, revealed that non-methylated polyisoprenylated benzophenones have greater antimicrobial activity. The results indicated in the resin of *C. grandiflora* pistillate flowers had higher activity than the resin of *C.*

grandiflora staminate flowers and it is due to the higher concentration of active compounds (polyisoprenylated benzophenones) in the resins of the pistillate flowers. The floral resins of most *Clusia* species tested presented antimicrobial

activity, especially in Gram-positive bacteria *S. aureus* and *B. subtilis* (Porto et al. 2000, Neves et al. 2007, Almeida et al. 2008).

Clusia burlemarxii, shrub vegetation found in Chapada Diamantina, Bahia, Brazil, was studied by Ribeiro et al. 2011. In addition to phytochemical research, the authors evaluated the antimicrobial activity of extracts and pure compounds against *Streptococcus mutans*, *S. aureus*, *B. subtilis*, *Micrococcus luteus*, *E. coli*, *Salmonella cholera*, *Pseudomonas aeruginosa*, *Aspergillus niger*, and *Cladosporium cladosporioides*. The extracts, as well as the isolated compounds, presented antimicrobial activity against Gram-positive bacteria, corroborating the results of different species of *Clusia* (Porto et al. 2000, Lokvam et al. 2000, Ribeiro et al. 2011).

The microdilution test on plates determined the MIC of extracts and isolated compounds. Nutrient broth and chloramphenicol were used as a culture medium for bacteria, malt, and olamine ciclopirox for fungi. The MIC was determined by the emergence of turbidity in the wells. Extracts were considered active when there was inhibition in concentration below or equal to 500 µg/mL and substances when there was inhibition below or equal to 100 µg/mL. The ethanolic extract of *C. burlemarxii* demonstrated a very promising activity against *B. subtilis* (31.25 µg/mL) and *S. aureus* (62.50 µg/mL) and the methanolic extract from the trunk against *B. subtilis* (62.50 µg/mL), *S. mutans* (62.50 µg/mL) and *M. luteus*. Four of the nine isolated substances presented strong antimicrobial activity with MIC of 25 µg/mL and moderate activity with MIC of 50 µg/mL (Ribeiro et al. 2011).

Antitumoral activity

Some isolated compounds of different species of *Clusia* have shown promising results in the search for new substances with antitumoral

activity. Nemorosone is one of these compounds and has been the target of studies by different research groups. Cuesta-Rubio et al. 2002 described *C. rosea* floral resin as a rich source of polyisoprenylated benzophenones, and after selective extraction of benzophenones and confirmation of a large amount of nemorosone, cytotoxic evaluation tests were performed where the compound was active for epithelioid carcinoma, prostate cancer, and central nervous system cancer (Camargo et al. 2015).

The criteria followed the recommendation of the National Cancer Institute of USA, which considers the significant activity of a product when the IC₅₀ is reached with a concentration less than 4 µg/mL. For epithelioid carcinoma, the IC₅₀ was 1.6 µg/mL for nemorosone; for prostate cancer, 3.6 µg/mL and for central nervous system cancer, 1.9 µg/mL (Cordell et al. 1993).

In search of pharmaceutical alternatives derived from natural products, the substance nemorosone was isolated from alcoholic extracts of *C. rosea* resins collected in Florida. The studies focused on neuroblastoma, a solid tumor common in childhood and characterized by rapid disease progression. The compound exerted intense activity in neuroblastoma cell lines, both in the matrix cell and in its clones selected for resistance to adriamycin, cisplatin, etoposide, or 5-fluorouracil, medicines widely used in the treatment of cancer (Díaz-Carballo et al. 2008). They found that the cytotoxic effect was due to apoptosis, thus not inducing an inflammatory response. This study demonstrated that nemorosone is a modulator or inhibitor of pathways that play roles in the transduction and integration of extracellular and intracellular oncogenic signals, making it a potential candidate for molecular therapy. The study also demonstrated that nemorosone exhibited cytotoxicity on leukemic cells, affecting protein levels, cell cycle progression, and low

cytotoxicity on non-tumor cells. *In vivo* studies have suggested that nemorosone significantly affected hematopoiesis in mice, making further studies even more attractive (Díaz-Carballo et al. 2008). Corroborating with previous studies, Popolo et al. 2011 also isolated nemorosone from *C. rosea* floral resins in search of therapeutic alternatives for breast cancer. The study reported that the substance could significantly inhibit cell growth at low concentrations, signaling to be a promising estrogen receptor antagonist and act in the prevention and treatment of breast cancer. Considering the potential of nemorosone and the need to test chemotherapy not only for anticancer or antitumor activity but also for potential mutagenicity, Camargo et al. 2013 carried out a study to determine the mutagenic and antimutagenic activity of the substance using the Ames test, using the TA97a, TA98, TA100 and the TA102 strains of *Salmonella typhimurium*, subjected to four different concentrations of the compound. The results indicated an absence of mutagenic activity.

The tests were carried out by associating nemorosone with direct (NPD and MMC) and indirect (AFL) mutagens in strains TA98, ta102, and TA100. The association of strain TA98 + NPD did not reduce the number of restricted colonies; TA100 + AFL caused a moderate protective effect with 31% inhibition. An expressive result was verified in the association of the strain TA102 + MMC, which presented a strong protective effect with an inhibition of 53%. The results suggest that nemorosone can potentially reduce the mutagenic damage of anticancer drug therapy, but further studies should be carried out to clarify its mechanism of action (Piccinelli et al. 2005). Another polyisoprenylated benzophenone, isolated from *C. rosea* and *C. grandiflora*, is 7-epi-nemorosone (4). The substance was described, in 2012, by Díaz-Carballo and collaborators as a potent antitumor agent with action on

prostate carcinoma. The study contributed to the search for new substances derived from plants to treat well-known diseases. Prostate cancer is a frequently diagnosed neoplasia and the second leading cause of cancer death in men due to metastases in distant organs due to resistance to available chemotherapy. The authors presented 7-epi-nemorosone (4) as a promising potential candidate to treat prostate cancer, with androgen-dependent cytotoxicity and absence of cross-resistance (Díaz-Carballo et al. 2012, Da Silva et al. 2019, Neves et al. 2007).

Nemorosone, as well as other polyisoprenylated benzophenones with a bicyclo[3.3.1]nonane-2,4,9-trione nucleus, have been the object of studies, demonstrating a great antitumor potential.

Bailón-Moscoso et al. 2016 studied the chemical composition of organic extracts from *Clusia latipes* leaves collected in Ecuador and evaluated the *in vitro* cytotoxicity and genotoxicity in human prostate cancer cells, colon cancer cells, astrocytoma cells, and breast cancer cells. The group presented results of purification and identification of friedelin, friedolan-3-ol and hesperidin, cytotoxic compounds active in the hexane extract. The three substances isolated were antiproliferative in selected cancer cells; however, the hexane extract of *C. latipes* induced a significant increase in DNA damage in exposed lymphocytes. The genotoxicity detected by the comet assay and the damage detected by this method is repairable DNA damage, requiring, according to the authors, further experiments to determine genotoxic effects and provide more consistent results. *Clusia paralicola* is another species of the genus that shows possible antitumor activity. Seo and coworkers isolated three biphenyl-derived compounds, clusiparalicoline A, B, and C, from the roots extracts by bioassay-guided fractionation using the DNA strand scission and human cancer cell

line KB cytotoxicity assays (Seo et al. 1999). The research showed that clusiparalicoline A and B were active in the DNA strand scission assay, while all three compounds exhibited modest cytotoxicity against the KB cell line. Further, *in vivo* biological studies will be needed to assess the antineoplastic potential of isolated compounds (Seo et al. 1999, Takaoka et al. 2002).

Antioxidant activity

The search for compounds with antioxidant activity is necessary since oxidative stress involves processes that cause imbalances in the human body, such as cancer, aging, and degenerative processes. Studies conducted with *Clusia* species (*C. lanceolata*, *C. paralicola*, *C. criuva* and *C. fluminensis*) focused on antioxidant activity have shown promising results. (Ferreira et al. 2014, Mazza et al. 2019, López-Alarcón & Denicola 2013, Athanasas et al. 2004, Wolf et al. 2017, Silva & Paiva 2012).

Ferreira et al. 2014 verified that extracts of leaves with galls of *C. lanceolata* presented higher antioxidant activity than those not galled and attributed this difference to the higher content of phenolic compounds and proanthocyanidins.

Seo et al. 1999 demonstrated that the ethanol extract from green fruits of *C. paralicola*, its fractions, and the isolated biflavonoids have potent antioxidant activity. Moreover, *C. criuva* also showed antioxidant potential. The methanolic extract of the fruit pericarps presented the highest percentage of maximum antioxidant activity at 250 µg / mL (Zhang et al. 2018). Silva and Paiva investigated the antioxidant potential of crude extracts of *Clusia fluminensis* through the neutralization of the stable free radical DPPH and the quantification of flavone and flavonoid content (Silva & Paiva 2012). The results pointed out a positive correlation between the presence of flavonoids and the

antioxidant activity of these extracts, and the researchers concluded that the acetonic extract of fruits of *C. fluminensis* is an exciting target for the search for substances with antioxidant activity, especially flavonoids (Athanasas et al. 2004, Silva & Paiva. 2012).

Although most studies link antioxidant activity to the presence of flavonoids, which is favored by the characteristic of its chemical structure, the study conducted by Silva et al. 2017 demonstrated that the antioxidant activity exhibited by *C. criuva* did not present a direct correlation with the presence of this type of substance. The authors suggest that the high values of the flavonoid content observed in hexane extracts may represent; in fact, to the presence of benzophenones that could have interacted with the aluminum chloride used in the quantification methodology.

Antinociceptive activity

The search for new substances with analgesic properties has grown in recent years. Antinociceptive activity was also observed in the *Clusia* species. Bittar et al. 2000 described the antinociceptive effects of I3, I18-binaringerin isolated from the methanol extract of *C. columnaris* collected in Venezuela. The substance did not increase the latency period of pain induced by thermal stimuli by discarding the relationship of its mechanism of action with opioid systems. However, it exhibited potent and dose-related antinociceptive properties, with ID₅₀ values of 22 µmol / kg in the writhing test and 28 µmol / kg in the second phase of the formalin test, values that suggest that the substance is more potent than some drugs clinically used as analgesics (Cordell et al. 1993).

Ferro et al. 2013 demonstrated the antinociceptive activity of hexane extract from *Clusia nemorosa* leaves in chemical pain models through mechanisms that suggest

the participation of the adrenergic systems pathways. The extract prevented visceral pain induced by acetic acid in mice for at least two hours. The study suggests that the mechanism may be partially linked to the inhibition of cyclooxygenase and lipoxygenase products and other inflammatory mediators in peripheral tissues, thus interfering in the signal transduction mechanism in primary afferent nociceptors.

To corroborate with studies of the antinociceptive activity of *Clusia* species, Mangas et al. 2019 evaluated the chemical composition and the potential antinociceptive effect of ethanol extract of *Clusia minor* leaves. Previous studies also demonstrated mechanical hypernociception induced by intraplantar carrageenan, tumor necrosis factor α (TNF α), and prostaglandin E2 (PGE2). The extract proved to be effective in reducing pain in a dose-dependent manner, in addition to inhibiting mechanical hypernociception of the paw, suggesting that the antinociceptive effect of *C. minor* occurs by the interaction of various mechanisms through central and peripheral pathways, capable of inflammatory and neurogenic pain.

Leishmanicidal activity

Leishmaniasis is an anthroponosis caused by approximately 20 species of a protozoa of the *Leishmania* genus, belonging to the family Trypanosomatidae, and transmitted by a bite of hematophagous female sandflies belonging to the Phlebotominae family. This is considered a neglected disease and one of the significant public health problems in the world, which affects 98 countries, 12 million cases, and 350 million people at risk of developing leishmaniasis, with 1.5 to 2 million new cases per year. Cases of leishmaniasis with the human immunodeficiency virus (HIV) co-infection are increasing and have been described in 35 countries (Wolf et al. 2017, Silva & Paiva 2012).

The leishmanicidal activity of methanol extracts from *Clusia flava* leaves was verified through *in vitro* bioassay. The extract of *C. flava* was able to inhibit the growth of promastigotes of *L. mexicana* with IC₅₀ 32 μ g/mL. As known of literature, IC₅₀ values between 3 and 49 μ g/mL are considered as a good inhibition of the microorganism (Peraza-Sánchez et al. 2007). Another study selected plant species used by chayahuite to cure cutaneous leishmaniasis. Forty extracts were evaluated, and among them, the aqueous extract of *Clusia amazonica* was considered with good IC₅₀ values, 32.9 μ g/mL (stems) and 34.6 μ g/mL (leaves) (Odonne et al. 2009).

Fruits of *Clusia gundlachii*, collected in Puerto Rico, were studied by Zhang et al. 2018 and, after fractionation, produced five new polycyclic chloroglucine derivatives that presented activity against intracellular amastigotes of macrophages and promastigotes of *Leishmania donovani*. The activity is comparable to those observed for the standard pentamidine drug.

Clusia pernambucensis, coming from the Brazilian cerrado, was the target of studies conducted by Silva et al. 2013. From the extract in ethyl acetate of the bark of the stem, it was possible to isolate Clusioxanthone. The substance was able to control macrophage infection with *Leishmania amazonensis* amastigotes. These results indicate that the species is a potential source of new compounds with leishmanicidal activity (Da Silva et al. 2017, Wolf et al. 2017).

Modulation of inflammatory processes

Clusia nemorosa is a common species in coastal forests of northeastern Brazil. Farias et al. 2012 evaluated the anti-inflammatory effect of this species leaves' hexane extract using carrageenan-induced mice pleurisy and cotton pellet-induced mice granuloma using the Boyden chamber assay and flow cytometry (Ferro et al. 2013).

The results were promising as they inhibited exudation, total leukocytes and neutrophils influx, and TNF α levels in carrageenan-induced pleurisy. Although the extract did not suppress the granulomatous tissue formation in the cotton pellet-induced granuloma test, the experiments showed that they revealed that the hexane extract of *C. nemorosa* inhibited neutrophil chemotaxis induced by CXCL1 in a dose-dependent manner, inhibited the chemoattraction of human neutrophils induced by formyl-methionyl-leucyl-phenylalanine (fMLP), leukotriene B4 (LTB4) and platelet activation factor (PAF). Further, *in vivo*, biological studies will be needed to assess the antineoplastic potential of isolated compounds (Seo et al. 1999, Takaoka et al. 2002).

Neutralization of toxic effects caused by *Bothrops* snake accidents

Researches related to neglected diseases are urgent and, as with malaria, dengue, tuberculosis and many other diseases, the risk of snakebite is always present, mainly in poorer areas, being an occupational and environmental risk added to poverty. Serum therapy, recommended in cases of snakebite accidents, acts on the systemic effects caused by the venom. However, the local effects, responsible for example for the amputations, draw attention to the need to search for antivenom support therapies. Extracts from different species of *Clusia*, such as *C. torressi*, *C. palmana* and *C. fluminensis* demonstrated positive effects in neutralizing the effects caused by snake venoms, exhibiting, for example, proteolytic, hemolytic and anti-hemorrhagic activity (Castro et al., 1999, Da Silva et al. 2019).

Da Silva et al. 2019 showed promising results in inhibiting the activities of *Bothrops jararaca* and *B. jararacussu* venoms, regardless of the experimental protocol used or the route of administration of the extracts. The presence

of tannins, flavonoids, saponins, steroids, and terpenoids was described. These results suggest that *C. fluminensis* extracts can be effective against some toxic effects of *B. jararaca* or *B. jararacussu* venom, a promising tool for treating accidents caused by such snakes. Thus, anti-venom properties of *C. fluminensis* extracts deserve further investigation (Da Silva et al. 2019).

Other activities

The hypotensive effect of *Clusia coclensis* aqueous extract was tested in normotensive and hypertensive animals, and a significant reduction in venous return was found in both rat strains. The extract caused a peripheral vasoconstrictor effect so the hypotensive and antihypertensive effect was attributed to a direct effect on the myocardium by a decrease in the strength of cardiac contraction (García-González & Matamoros 1998, 1996).

Mazza et al. 2019 described the presence of potentially bioactive compounds in aril extracts from *Clusia fluminensis* fruits, including the carotenoid zeaxanthin, described as an important macular protector and regenerator. The concentration of zeaxanthin (0,823 mg/g), higher than that found in other plant matrices, indicates that the species may be a potential source of bioactive substances. Other studies with *Clusia fluminensis* identified biopesticide activity in hexane extracts of fruits and flowers, and the Clusianone was isolated from the species. The study measured the larvicidal potential of extracts and substances, contributing to the search for less toxic natural insecticides for humans and the environment as alternatives to traditional control of the culicid (Duprat et al. 2017).

Anholeti et al. 2015a also evaluated the effects of the hexane extracts of the fruits and flowers of *Clusia fluminensis* and the

main component of flower extract, a purified benzophenone Clusianone, against *Aedes aegypti*. Although the treatment of larvae with fruit and flower extracts of *C. fluminensis* did not affect the survival of *A. aegypti* (50 mg / L), it significantly delayed the development of the mosquito. The Clusianone isolated (50 mg / L) of flower extract killed 93.3% of larvae and completely blocked the development of *A. aegypti*. The results reinforce the importance of developing Clusianone as a biopesticide to control vectors of insects of tropical diseases (Duprat et al. 2017).

Clusia hilariana was the target of studies conducted by Kelecom et al. 2002. The methanolic extracts of staminate flowers promoted food inhibition in 4th stage larvae of *Rhodnius prolixus* (one of the vectors of Chagas Disease) in addition to the delay of ecdysis. Isolated oleanolic acid promoted toxicity over larvae of the 4th stage of *R. prolixus* and was also able to delay ecdysis. The mixture of benzophenones isolated from the species also promoted the delay in the ecdysis of larvae of the 4th stage of *R. prolixus*.

Corroborating the biological potential of *Clusia paralicola*, previously reported with antitumor activity (Seo et al. 1999), the species was also studied by Takaoka et al. 2002 who found that clusiparalicoline A, a prenylated and geranylated biphenyl compound isolated from the roots of *C. paralicola* through sequential Stille reactions and palladium-catalyzed Suzuki-Miyaura reactions, exhibited potent activity for promoting neurite outgrowth in a primary culture of fetal rat cortical neurons. The results presented encourage further studies on the structure-activity relationship of compounds isolated from the species to elucidate mechanisms of action and the biological activity of therapeutic prototypes of plant origin.

CONCLUSION

The value of plant species as a source of molecules with therapeutic potential is historically known. The challenges associated with the process capable of transforming the plant into medicine are numerous and can only be overcome with interdisciplinary knowledge. In this review, we seek to provide information about some approaches of the research of the genus *Clusia*, focusing on biological activities. The genus was found to have bioactive properties, including antibacterial, antitumor, antivenom, insecticide, anti-inflammatory, antioxidant, smooth muscle relaxant, neuroprotective and antiprotozoal.

The studies demonstrated were conducted with extracts and compounds isolated from different parts of the *Clusia* species, and the promising results deserve further investigation. A summary of the information related to the therapeutic potential of *Clusia* will undoubtedly add value to research on the genus.

Acknowledgments

The authors thank the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance code 001 and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro - FAPERJ.

REFERENCES

- ALMEIDA LS, MURATA RM, YATSUDA R, DOS SANTOS MH, NAGEM TJ, ALENCAR SM, KOO H & ROSALEN PL. 2008. Antimicrobial activity of *Rhedia brasiliensis* and 7-epiClusianone against *Streptococcus mutans*. *Phytomedicine* 15(10): 886-891.
- ALVES TM, ALVES R, ROMANHA AJ, ZANI CL, SANTOS MH & NAGEM TJ. 1999. Biological activities of 7-epiClusianone. *J Nat Prod* 62(2): 369-371.
- ALVES TMA, SILVA AF, BRANDÃO M, GRANDI TSM, SMÂNIA EFA, SMÂNIA JÚNIOR A & ZANI CL. 2000. Biological screening of Brazilian medicinal plants. *Mem Inst Oswaldo Cruz* 95 (3): 367-373.
- ANHOLETI MC, DUPRAT RC, FIGUEIREDO MR, KAPLAN MA, SANTOS MG, GONZALEZ MS, RATCLIFFE NA, FEDER D, PAIVA SR & MELLO C.

- B. 2015a. Biocontrol evaluation of extracts and a major component, Clusianone, from *Clusia fluminensis* Planch. & Triana against *Aedes aegypti*. Mem Inst Oswaldo Cruz 110(5): 629-635.
- ANHOLETI MC, PAIVA SR, FIGUEIREDO MR & KAPLAN MA. 2015b. Chemosystematic aspects of polyisoprenylated benzophenones from the genus *Clusia*. An Acad Bras Cienc 87: 289-301.
- ANHOLETI MC, SILVA KMM, MORAES MG, SANTOS MG, FIGUEIREDO MR, KAPLAN MAC, JOFFILY A & PAIVA SR. 2017. Leaf anatomy and epicuticular waxes composition of *Clusia fluminensis* Planch. & Triana (Clusiaceae). Arab J Med Aromat 3: 68-86.
- ATHANASAS K, MAGIATIS P, FOKIALAKIS N, SKALTSOUNIS AL, PRATSINIS H & KLETSAS D. 2004. Hyperjovinols A and B: Two new phloroglucinol derivatives from *Hypericum jovis* with antioxidant activity in cell cultures. J Nat Prod 67(6): 973-977.
- BAILÓN-MOSCOSO N, ROMERO-BENAVIDES JC, SORDO M, VILLACÍS J, SILVA R, CELI L, MARTÍNEZ-VÁZQUEZ M & OSTROSKY-WEGMAN P. 2016. Phytochemical study and evaluation of cytotoxic and genotoxic properties of extracts from *Clusia latipes* leaves. Rev Bras Farmacogn 26(1): 44-49.
- BARRIOS M, CALVO M, ARGUEDAS E & CASTRO O. 1991. Epicatequina en *Clusia stenophylla* y *Clusia flava*. Ing Cienc Quim 13: 27-28.
- BITTAR M, SOUZA MM, YUNES RA, LENTO R, DELLE MONACHE F & CECHINEL FILHO V. 2000. Antinociceptive activity of I3, I18-binaringenin, a biflavonoid present in plants of the guttiferae. Planta Med 66(1): 84-86.
- CAMARGO MS, OLIVEIRA MT, SANTONI MM, RESENDE FA, OLIVEIRA-HOHNE AP, ESPANHAM LG, NOGUEIRA CH, CUESTA-RUBIO O, VILEGAS W & VARANDA E. 2015. Effects of nemorosone, isolated from the plant *Clusia rosea*, on the cell cycle and gene expression in MCF-7 BUS breast cancer cell lines. Phytomedicine 22(1): 153-157.
- CAMARGO MS ET AL. 2013. Evaluation of estrogenic, antiestrogenic and genotoxic activity of nemorosone, the major compound found in brown Cuban propolis. BMC Complement Med 13: 201.
- CASTRO O, GUTIERREZ JM, BARRIOS M, CASTRO I, ROMERO M & UMANA E. 1999. Neutralization of the hemorrhagic effect induced by *Bothrops asper* (Serpentes: Viperidae) venom with tropical plant extracts. Rev Biol Trop 47(3): 605-616.
- CORDELL GA, KINGHORN AD & PEZZUTO JM. 1993. Separation, structure elucidation and bioassay of cytotoxic natural products, In: Bioactive Natural Products: Detection, Isolation and Structure Determination Colegate SM and Molyneux RJ Eds. CRC Press Boca Raton 199-200.
- CUESTA-RUBIO O, FRONTANA-URIBE BA, RAMÍREZ-APAN T & CÁRDENAS J. 2002. Polyisoprenylated benzophenones in cuban propolis; biological activity of nemorosone. J Biosci 57(3-4): 372-378.
- DA SILVA AR, ANHOLETI MC, PIETROLUONGO M, SANCHEZ EF, VALVERDE AL, DE PAIVA SR, FIGUEIREDO MR, KAPLAN MAC & FULY AL. 2019. Utilization of the Plant *Clusia fluminensis* Planch & Triana Against Some Toxic Activities of the Venom of *Bothrops jararaca* and *B. jararacussu* Snake Venom Toxic Activities. Curr Top Med Chem 19(22): 1990-2002.
- DA SILVA KMM, NÓBREGA AB, LESSA B, ANHOLETI MC, LOBÃO AQ, VALVERDE AL, PAIVA SR & JOFFILY A. 2017. *Clusia criuva* Cambess. (Clusiaceae): anatomical characterization, chemical prospecting and antioxidant activity. An Acad Bras Cienc 89: 1565-1578.
- DÍAZ-CARBALLO D, GUSTMANN S, ACIKELLI AH, BARDENHEUER W, BUEHLER H, JASTROW H, ERGUN S & STRUMBER D. 2012. 7-epi-nemorosone from *Clusia rosea* induces apoptosis, androgen receptor down-regulation and dysregulation of PSA levels in LNCaP prostate carcinoma cells. Phytomedicine 19(14): 1298-1306.
- DÍAZ-CARBALLO D, MALAK S, BARDENHEUER W, FREISTUEHLER M & REUSCH HP. 2008. Cytotoxic activity of nemorosone in neuroblastoma cells. J Cell Mol Med 12(6B): 2598-2608.
- DUPRAT RC ET AL. 2017. Laboratory evaluation of *Clusia fluminensis* extracts and their isolated compounds against *Dysdercus peruvianus* and *Oncopeltus fasciatus*. Rev Bras Farmacogn 27: 59-66.
- FARIAS JA ET AL. 2012. Modulation of inflammatory processes by leaves extract from *Clusia nemorosa* both *in vitro* and *in vivo* animal models. Inflammation 35(2): 764-771.
- FENNER R, BETTI AH, MENTZ LA & RATES SMK. 2006. Plantas utilizadas na medicina popular brasileira com potencial atividade antifúngica. Rev Bras Ciênc farm 42(3): 369-394.
- FERREIRA RO, JUNIOR ARC, SILVA TMG, CASTRO RN, SILVA TMS & CARVALHO MG. 2014. Distribution of metabolites in galled and non-galled leaves of *Clusia lanceolata* and its antioxidant activity. Rev Bras Farmacogn 24(6): 617-625.
- FERRO JNS, SILVA JP, CONSERVA LM & BARRETO E. 2013. Leaf extract from *Clusia nemorosa* induces an antinociceptive effect in mice via a mechanism that is adrenergic systems dependent. Chin J Nat Med 11(4): 385-390.
- GARCÍA-GONZÁLEZ M & MATAMOROS OM. 1996. Cardiovascular effects of aqueous extracts of the leaves of *Clusia coclensis* (Guttiferae). Rev Biol Trop 44(1): 87-91.

- GARCÍA-GONZÁLEZ M & MATAMOROS OM. 1998. Acción vaso-periférica del extracto acuoso de las hojas de *Clusia coclensis* (Clusiaceae). *Rev Biol Trop* 46(3): 575-578.
- GASPAROTTO JÚNIOR A, BREZAN MA, PILOTO IC, CORTEZ, DAG, NAKAMURA CV, DIAS FILHO BP, RODRIGUES FE & FERREIRA AG. 2005. Estudo fitoquímico e avaliação da atividade moluscicida do *Calophyllum brasiliense* Camb (Clusiaceae). *Quim Nova* 28(4): 575-578.
- GUSTAFSON K, BLUNT J, MUNRO M, FULLER R, MCKEE T, CARDELLINA J, MCMAHON J, CRAGG G & BOYD M. 1992. The guttiferones, HIV-inhibitory benzophenones from *Symphonia globulifera*, *Garcinia livingstonei*, *Garcinia ovalifolia* and *Clusia rosea*. *Tetrahedron* 48: 10093-10102.
- HUERTA-REYES M, BASUALDO MDEL C, LOZADA L, JIMENEZ-ESTRADA M, SOLER C & REYES-CHILPA R. 2004. HIV-1 inhibition by extracts of Clusiaceae species from Mexico. *Biol Pharm Bull* 27(6): 916-920.
- JAYASURIYA H, CLARK AM & MCCHESENEY JD. 1991. New antimicrobial filicinic acid derivatives from *Hypericum drummondii*. *J Nat Prod* 54(5): 1314-1320.
- KELECOM A, REIS GL, FEVEREIRO PC, SILVA JG, SANTOS MG, MELLO NETO CB, GONZALEZ MS, GOUEVA RC & ALMEIDA GS. 2002. A multidisciplinary approach to the study of the fluminense vegetation. *An Acad Bras Cienc* 74: 171-181.
- LANGENHEIN JH. 2003. Plant resins: chemistry, evolution, ecology and ethnobotany. Hong Kong: Timber Press, 586 p.
- LOKVAM J, BRADDOCK JF, REICHARDT PB & CLAUSEN TP. 2000. Two polyisoprenylated benzophenones from the trunk latex of *Clusia grandiflora* (Clusiaceae). *Phytochemistry* 55(1): 29-34.
- LÓPEZ-ALARCÓN C & DENICOLA A. 2013. Evaluating the antioxidant capacity of natural products: a review on chemical and cellular-based assays. *Anal Chim Acta* 763: 1-10.
- LUTTGE U. 2006. Photosynthetic flexibility and ecophysiological plasticity: questions and lessons from *Clusia*, the only CAM tree, in the neotropics. *New Phytologist* 171: 7-25.
- MANGAS R, REYNALDO G, VECCHIA MT, AVER K, PIOVESAN LG, BELLO A, RODEIRO I, MALHEIROS A, SOUZA MM & MENENDEZ R. 2019. Gas Chromatography/Mass Spectrometry characterization and antinociceptive effects of the ethanolic extract of the leaves from *Clusia minor* L. *J Pharm Pharmacogn Res* 7: 21-30.
- MÁRQUEZ N, SANCHO R, BEDOYA LM, ALCAMÍ J, LÓPEZ-PÉREZ JL, FELICIANO AS, FIEBICH BL & MUÑOZ E. 2005. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway. *Antiviral Res* 66(2-3): 137-145.
- MAZZA KEL, SANTIAGO MCPA, PACHECO S, NASCIMENTO LSM, BRAGA ECO, MARTINS VC, CUNHA CP, GODOY RLO & BORGUINI RG. 2019. Determinação de Substâncias Bioativas em Arilos dos Frutos de *Clusia fluminensis* Planch. & Triana. *Rev Virtual Quim* 11(1): 3-17.
- MELO CL ET AL. 2009. Betulinic acid, a natural pentacyclic triterpenoid, prevents abdominal fat accumulation in mice fed a high-fat diet. *J Agric Food Chem* 57(19): 8776-8781.
- MENESES LC, RIBEIRO MS, ANHOLETI MC, FIGUEIREDO MR, KAPLAN MAC, SANTOS MG, PEREIRA HS & PAIVA SR & PAIXÃO ICNP. 2015. Cytotoxicity and antiviral activity of extracts and compounds isolated from *Clusia fluminensis*. *DST - J Bras Doenças Sex Transm* 27: 73-78.
- NEVES JS, COELHO LP, CORDEIRO RS, VELOSO MP, RODRIGUES E SILVA PM, DOS SANTOS MH & MARTINS MA. 2007. Antianaphylactic properties of 7-epiClusianone, a tetraprenylated benzophenone isolated from *Garcinia brasiliensis*. *Planta Medic* 73(7): 644-649.
- NGUEMEVING JR, AZEBAZE AGB, KUETE V, ERIC CARLY NN, BENG VP, MEYER M, BLOND A, BODO B & NKENGFAK AE. 2006. Laurentixanones A and B, antimicrobial xanones from *Vismia laurentii*. *Phytochemistry* 67(13): 1341-1346.
- NKENGFAK AE, MKOUNGA P, MEYER M, FOMUM ZT & BODO B. 2002. Globulixanones C, D and E: three prenylated xanones with antimicrobial properties from the root bark of *Symphonia globulifera*. *Phytochemistry* 61(2): 181-187.
- ODONNE G, BOURDY G, CASTILLO D, ESTEVEZ Y, LANCHANGA A, ALBAN-CASTILLO J, DEHARO E, ROJAS R, STIEN D & SAUVAIN M. 2009. Ta'ta', Huayani: perception of leishmaniasis and evaluation of medicinal plants used by the Chayahuita in Peru. Part II. *J Ethnopharmacol* 126(1): 149-1458.
- OLIVEIRA CMA, PORTO ALM, BITTRICH V & MARSAIOLI AJ. 1999. Two polyisoprenylated benzophenones from the floral resins of three *Clusia* species. *Phytochemistry* 50(6): 1073-1079.
- OLIVEIRA EC, ANHOLETI MC, DOMINGOS TF, FAIOLI CN, SANCHEZ EF, DE PAIVA SR & FULY AL. 2014. Inhibitory effect of the plant *Clusia fluminensis* against biological activities of *Bothrops jararaca* snake venom. *Nat Prod Commun* (1): 21-25.
- OLIVEIRA RF, CAMARA CA, AGRAB MF & SARMENTO TMS. 2012. Biflavonoids from the Unripe Fruits of *Clusia paralicola* and their Antioxidant Activity. *Nat Prod Commun* 7(12): 1597-1600

- PECCHIO M, SOLÍS PN, LÓPEZ-PÉREZ JL, VASQUEZ Y, RODRÍGUEZ N, OLMEDO D, CORREA M, SAN FELICIANO A & GUPTA MP. 2006. Cytotoxic and antimicrobial benzophenones from the leaves of *Tovomita longifolia*. *J Nat Prod* 6(3): 410-413.
- PERAZA-SÁNCHEZ SR, CEN-PACHECO F, NOH-CHIMAL A, MAY-PAT F, SIMÁ-POLANCO P, DUMONTEIL E, GARCÍA-MISS MR & MUT-MARTÍN M. 2007. Leishmanicidal evaluation of extracts from native plants of the Yucatan peninsula. *Fitoterapia* 78(4): 315-318.
- PICCINELLI AL, CUESTA-RUBIO O, CHICA MB, MAHMOOD N, PAGANO B, PAVONE M, BARONE V & RASTRELLI L. 2005. Structural revision of Clusianone and 7-epi-Clusianone and anti-HIV activity of polyisoprenylated benzophenones. *Tetrahedron* 61(34): 8206-8211.
- POPOLO A, PICCINELLI AL, MORELLO S, SORRENTINO R, OSMANY CR, RASTRELLI L & PINTO A. 2011. Cytotoxic activity of nemorosone in human MCF-7 breast cancer cells. *Can J Physiol Pharmacol* 89(1): 50-57.
- PORTO AL, MACHADO SM, OLIVEIRA CM, BITTRICH V, AMARAL MC & MARSAIOLI AJ. 2000. Polyisoprenylated benzophenones from *Clusia* floral resins. *Phytochemistry* 55(7): 755-768.
- REUTRAKUL V, ANANTACHOKE N, POHMAKOTR M, JAIPETCH T, SOPHASAN S, YOOSOOK C, KASISIT J, NAPASWAT C, SANTISUK T & TUCHINDA P. 2007. Cytotoxic and anti-HIV-1 caged xanthenes from the resin and fruits of *Garcinia hanburyi*. *Planta Medic* 73(1): 33-40.
- RIBEIRO PR, FERRAZ CG, GUEDES ML, MARTINS D & CRUZ FG. 2011. A new biphenyl and antimicrobial activity of extracts and compounds from *Clusia burllemarxii*. *Fitoterapia* 82(8): 1237-1240.
- RUKACHAISIRIKUL V, PAILEE P, HIRANRATA, TUCHINDA P, YOOSOOK C, KASISIT J, TAYLOR WC & REUTRAKUL V. 2003. Anti-HIV-1 protostane triterpenes and digeranylbenzophenone from trunk bark and stems of *Garcinia speciosa*. *Planta Med* 69(12): 1141-1146.
- SACRAMENTO CK, COELHO JE, CARVALHO JEU, MÜLLER CH & NASCIMENTO WMO. 2007. Cultivo do mangostão no Brasil. *Rev Bras Fruticultura* 29(1): 195-203.
- SALEHI B ET AL. 2018. Medicinal Plants Used in the Treatment of Human Immunodeficiency Virus. *Int J Mol Sci* 19(5): 1459.
- SANZ-BISET J, CAMPOS-DE-LA-CRUZ J, EPIQUIEN-RIVERA MA & CAÑIGUERAL SA. 2009. A first survey on the medicinal plants of the Chazuta valley (Peruvian Amazon). *J Ethnopharmacol* 122(2): 333-362.
- SEO EK, HUANG L, WALL ME, WANI MC, NAVARRO H, MUKHERJEE R, FARNSWORTH NR & KINGHORN AD. 1999. New biphenyl compounds with DNA strand-scission activity from *Clusia paralicola*. *J Nat Prod* 62(11): 1484-1487.
- SILVA EA, FILHA RF, SILVEIRA L, LOPES ED, PAULA N, BRAZ-FILHO J & LAILA RE. 2013. Clusioxanthone and Tocotrienol Series from *Clusia pernambucensis* and their Antileishmanial Activity. *J Braz Chem Soc* 24: 1314-1324.
- SILVA KMM, NÓBREGA AB, LESSA B, ANHOLETI MCA, LOBÃO AQ, VALVERDE AL, PAIVA SR & JOFFILY A. 2017. *Clusia criuva* Cambess. (Clusiaceae): anatomical characterization, chemical prospecting and antioxidant activity. *An Acad Bras Cienc* 89: 1565-1578.
- SILVA MC & PAIVA SR. 2012. Antioxidant activity and flavonoid content of *Clusia fluminensis* Planch. & Triana. *An Acad Bras Cienc* 84: 609-616.
- SPINO C, DODIER M & SOTHEESWARAN S. 1998. Anti-HIV coumarins from *Calophyllum* seed oil. *Bioorg Med Chem Lett* (24): 3475-3478.
- SUFFREDINI IB, PACIENCIA ML, NEPOMUCENO DC, YOUNES RN & VARELLA AD. 2006. Antibacterial and cytotoxic activity of Brazilian plant extracts of Clusiaceae. *Mem Inst Oswaldo Cruz* 101(3): 287-290.
- TAKAOKA S, NAKADE K & FUKUYAMA Y. 2002. The first total synthesis and neurotrophic activity of clusiparalicoline A, a prenylated and geranylated biaryl from *Clusia paralicola*. *Tetrahedron Lett* 43(39): 6919-6923.
- VALLI M, RUSSO HM & BOLZANI VS. 2018. The potential contribution of the natural products from Brazilian biodiversity to bioeconomy. *An Acad Bras Cienc* 90: 763-778.
- WINTER K, GARCIA M & HOLTUM JA. 2008. On the nature of facultative and constitutive CAM: environmental and developmental control of CAM expression during early growth of *Clusia*, *Kalanchoe*, and *Opuntia*. *J Exp Bot* 59(7): 1829-1840.
- WINTER K, GARCIA M & HOLTUM JA. 2009. Canopy CO₂ exchange of two neotropical tree species exhibiting constitutive and facultative CAM photosynthesis, *Clusia rosea* and *Clusia cylindrica*. *J Exp Bot* 60(11): 3167-3177.
- WOLF NP, DE MELLO TFP, NAVASCONI TR, MOTA CA, DEMARCHI IG, ARISTIDES SMA, LONARDONI MVC, TEIXEIRA JVV & SILVEIRA TGV. 2017. Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review. *Parasitology* 144(8): 995-1004.
- WU SB, LONG C & KENNELLY EJ. 2014. Structural diversity and bioactivities of natural benzophenones. *Nat Prod Rep* 31(9): 1158-1174.

YASUNAKA K, ABE F, NAGAYAMA A, OKABE H, LOZADA-PÉREZ L, LÓPEZ-VILLAFRANCO E, MUÑIZ EE, AGUILAR A & REYES-CHILPA R. 2005. Antibacterial activity of crude extracts from Mexican medicinal plants and purified coumarins and xanthenes. *J Ethnopharmacol* 97(2): 293-299.

YIMDJIO MC, AZEBAZE AG, NKENGFACK AE, MEYER AM, BODO B & FOMUM ZT. 2004. Antimicrobial and cytotoxic agents from *Calophyllum inophyllum*. *Phytochemistry* 65(20): 2789-2795.

ZHANG J, ZHAO J, SAMOYLENKO V, JAIN S, TEKWANI BL, MUHAMMAD I. 2018. New Polyisoprenylated Polycyclic Phloroglucines from *Clusia gundlachii*. *Nat Prod Commun* 13(3): 361-365.

How to cite

PIETROLUONGO M, ANHOLETI MC, FULY AL, VALVERDE AL & PAIVA SR. 2024. Biological Activities of Species of the Genus *Clusia* L (Clusiaceae): A General Approach. *An Acad Bras Cienc* 96: e20220649. DOI 10.1590/0001-3765202420220649.

Manuscript received on July 27, 2022;
accepted for publication on November 23, 2023

MÁRCIA PIETROLUONGO^{1,2}

<https://orcid.org/0000-0002-3944-6486>

MARIA CAROLINA ANHOLETI³

<https://orcid.org/0000-0003-1552-9161>

ANDRÉ L. FULY⁴

<https://orcid.org/0000-0002-5265-52580>

ALESSANDRA L. VALVERDE^{2,5}

<https://orcid.org/0000-0002-1250-1051>

SELMA R. DE PAIVA^{2,6}

<https://orcid.org/0000-0002-8295-7011>

¹Vice-diretoria de Pesquisa, Ensino e Inovação, Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz, Laboratório de Farmacotécnica Experimental, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250 Rio de Janeiro, RJ, Brazil

²Programa de Pós-Graduação em Ciências aplicadas à Produtos para Saúde/PPGCAPS, Universidade Federal Fluminense, Faculdade de Farmácia, Rua Dr. Mário Vianna, 523, Santa Rosa, 24241-000 Niterói, RJ, Brazil

³Universidade Federal do Paraná, Setor de Ciências da Saúde, Departamento de Farmácia, Avenida Prefeito Lothário Meissner, 632, Jardim Botânico, 80210-170 Curitiba, PR, Brazil

⁴Universidade Federal Fluminense, Instituto de Biologia, Departamento de Biologia Celular e Molecular, Rua Prof. Marcos Waldemar de Freitas Reis, s/n, São Domingos, 24210-201 Niterói, RJ, Brazil

⁵Universidade Federal Fluminense, Instituto de Química, Departamento de Química Orgânica, Outeiro de São João Batista, s/n, Campus do Valonguinho, 24020-141 Niterói, RJ, Brazil

⁶Universidade Federal Fluminense, Instituto de Biologia, Departamento de Biologia Geral, Rua Prof. Marcos Waldemar de Freitas Reis, s/n, São Domingos, 24210-201 Niterói, RJ, Brazil

Correspondence to: **Márcia Pietroluongo**

E-mail: marcia.pietroluongo@fiocruz.br

Author contributions

Conceptualization, methodology, writing—original draft M.P., M.C.A., A.L.V. and S.R.P.; funding acquisition, A.L.V., A.L.F. and S.R.P.; investigation, writing—review and editing, M.P., M.C.A., A.L.F., A.L.V. and S.R.P.; resources, A.L.V. and S.R.P.; supervision, M.C.A., A.L.V. and S.R.P.; All authors have read and agreed to the published version of the manuscript.

